客服中心
关注我们
全国服务热线：
18086415513
赛培新增产品文章：人TNF-α、 IL-6、MMP-2、MMP-9 和 SDF-1 ELISA试剂盒
发布时间：2022-09-16 16:37:55
左卡尼汀联合金水宝治疗维持性血液透析 慢性肾功能衰竭患者的临床效果观察
何雪1，殷芳2 ( 重庆医科大学附属永川医院 1． 肾病风湿科，2． 感染科，重庆 402160) ［摘要］ 目的: 观察左卡尼汀联合金水宝治疗维持性血液透析慢性肾功能衰竭患者的临床效果。方法: 选择 2018 年 6 月至 2021 年 2 月在重庆医科大学附属永川医院行维持性血液透析的慢性肾功能衰竭患者 92 例，随机分 为治疗组( n = 46) 和对照组( n = 46) 。对照组采用左卡尼汀治疗，治疗组在对照组基础上联合金水宝治疗。比较 两组临床疗效以及血清中炎症因子、基质金属蛋白酶( MMP) 、营养指标、基质细胞衍生因子-1( SDF-1) 、维生素 D 及维生素 B12 水平。结果: 治疗后，治疗组临床总有效率( 89． 13% ) 显著高于对照组( 69． 57% ，P ＜ 0． 05) 。治疗 后，两组肿瘤坏死因子-α( TNF-α) 、IL-6、C 反应蛋白( CＲP) 、MMP-2、MMP-9、SDF-1 水平较治疗前明显降低( P 均 ＜ 0． 05) ，总蛋白、白蛋白、血红蛋白、维生素 D、维生素 B12 水平较治疗前明显升高( P 均 ＜ 0． 05) ; 且治疗组 TNF-α、 IL-6、CＲP、MMP-2、MMP-9、SDF-1 水平明显低于对照组( P 均 ＜ 0． 05) ，总蛋白、白蛋白、血红蛋白、维生素 D、维生素 B12 水平明显高于对照组( P 均 ＜ 0． 05) 。两组不良反应、并发症发生率比较，差异无统计学意义( P 均 ＞ 0． 05) 。结 论: 左卡尼汀联合金水宝治疗可提高维持性血液透析慢性肾功能衰竭患者临床效果，减轻微炎症反应，改善营养状 态。 ［关键词］ 左卡尼汀; 金水宝; 慢性肾功能衰竭; 维持性血液透析; 基质金属蛋白酶; 基质细胞衍生因子-1; 维生素 D; 维生素 B12 ［中图分类号］ Ｒ459． 5; Ｒ692． 5 ［文献标志码］ A ［文章编号］ 1671 － 7783( 2022) 02 － 0156 － 05 DOI: 10． 13312 /j． issn． 1671-7783． y210117 ［引用格式］何雪，殷芳． 左卡尼汀联合金水宝治疗维持性血液透析慢性肾功能衰竭患者的临床效果观察［J］． 江 苏大学学报( 医学版) ，2022，32( 2) : 156 － 160，166． ［基金项目］重庆市教育委员会项目( KJQN201900420) ［作者简介］何雪( 1990—) ，女，硕士研究生，住院医师; 殷芳( 通讯作者) ，E-mail: Ahappy2021@ 126． com
Clinical efficacy of levocarnitine combined with Jinshuibao in the treatment of patients with chronic renal failure undergoing maintenance hemodialysis
HE Xue1，YIN Fang2 ( 1． Department of Nephrology and Ｒheumatology，2． Department of Infection，Yongchuan Hospital Affiliated to Chongqing Medical University，Chongqing 402160，China) ［Abstract］ Objective: To evaluate the clinical effect of levocarnitine combined with Jinshuibao on patients with chronic renal failure patients undergoing maintenance hemodialysis． Methods: Ninety-two patients with chronic renal failure who underwent maintenance hemodialysis in Yongchuan Hospital Affiliated to Chongqing Medical University from June 2018 to February 2021 were selected in the study， and were randomly divided into the treatment group ( n = 46) and the control group ( n = 46) ． The control group was treated with levocarnitine，and the treatment group was treated with Jinshuibao on the basis of the control group． Clinical efficacy and level of inflammatory factors，matrix metalloproteinases， nutritional indicators，stromal cell-derived factor-1 ( SDF-1) ，vitamin D and vitamin B12 in serum were compared between the two groups． Ｒesults: After treatment，the total clinical effective rate of treatment group ( 89． 13% ) was significantly higher than that of control group ( 69． 57% ，P ＜ 0． 05 ) ． After treatment，the levels of tumor necrosis factor-α ( TNF-α) ，IL-6，C-reactive protein ( CＲP) ，matrixmetalloproteinase-2 ( MMP-2 ) ，matrix metalloproteinase-9 ( MMP-9 ) and SDF-1 in 2 groups were significantly decreased compared with before treatment ( all P ＜ 0． 05 ) ． The levels of total protein， albumin，hemoglobin，vitamin D and vitamin B12 were higher than those before treatment ( all P ＜ 0． 05) ; and the contents of TNF-α，IL-6，CＲP，MMP-2，MMP-9 and SDF-1 in treatment group were lower than those in control group ( P ＜ 0． 05) ，and the levels of total protein，albumin，hemoglobin， vitamin D and vitamin B12 in treatment group were higher than those in control group( P ＜ 0． 05) ． There was no significant difference in the incidence of adverse reactions and complication between the two groups( both P ＞ 0． 05) ． Conclusion: Levocarnitine combined with Jinshuibao could improve the clinical efficacy，reduce micro-inflammatory reaction，improve nutritional status in patients with chronic renal failure undergoing maintenance hemodialysis． ［Key words］ levocarnitine; Jinshuibao; chronic renal failure; maintenance hemodialysis; matrix metalloproteinase; stromal cell derived factor-1; Vitamin D; Vitamin B12
左卡尼汀联合金水宝治疗维持...功能衰竭患者的临床效果观察_何雪.pdf
